EcoDrugPlus

Matrix Metallopeptidase 9 Gene 1

Ensembl ID : ENSXETG00000008703
Gene Symbol: MMP9.1
18 Enzyme and pathways 5 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSXETG00000017426
Gene Symbol: MTOR
24 Enzyme and pathways 5 View Cross-references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 1 Receptor

Ensembl ID : ENSXETG00000041570
Gene Symbol: MC1R
7 Enzyme and pathways 5 View Cross-references
159 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 3 Receptor

Ensembl ID : ENSXETG00000048875
Gene Symbol: MC3R
7 Enzyme and pathways 5 View Cross-references
138 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 4 Receptor

Ensembl ID : ENSXETG00000040571
Gene Symbol: MC4R
7 Enzyme and pathways 4 View Cross-references
121 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1a

Ensembl ID : ENSXETG00000017134
Gene Symbol: MTNR1A
6 Enzyme and pathways 5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1b

Ensembl ID : ENSXETG00000047022
Gene Symbol: MTNR1B
6 Enzyme and pathways 2 View Cross-references
107 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Membrane Metalloendopeptidase

Ensembl ID : ENSXETG00000007771
Gene Symbol: MME
9 Enzyme and pathways 5 View Cross-references
229 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Methionyl Aminopeptidase 2

Ensembl ID : ENSXETG00000009238
Gene Symbol: METAP2
4 Enzyme and pathways 5 View Cross-references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Microtubule Associated Protein Tau

Ensembl ID : ENSXETG00000003240
Gene Symbol: MAPT
5 Enzyme and pathways 5 View Cross-references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSXETG00000018576
Gene Symbol: MAPK1
114 Enzyme and pathways 5 View Cross-references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSXETG00000006199
Gene Symbol: MAPK10
31 Enzyme and pathways 5 View Cross-references
147 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).